Association between genetic polymorphisms of cytochrome P450 2C19 and the risk of cerebral ischemic stroke in Chinese

被引:14
|
作者
Gu, Shuzhen [1 ,2 ]
Sun, Yan [3 ]
Han, Ruifa [4 ]
Wang, Lin [4 ]
Wang, Dongliang [1 ]
Wang, Jizuo [1 ]
Li, Xin [1 ]
机构
[1] Tianjin Med Univ, Hosp 2, Dept Neurol, Tianjin 300211, Peoples R China
[2] Zhengzhou Univ, Luoyang Cent Hosp, Dept Electromyog, Luoyang 471009, Peoples R China
[3] Tianjin Med Univ, Hosp 2, Tianjin Inst Urol, Tianjin 300211, Peoples R China
[4] Tianjin Med Univ, Hosp 2, Dept Gerontol, Tianjin 300211, Peoples R China
关键词
Cerebral ischemic stroke; CYP2C19; Genetic polymorphism; CLINICAL-OUTCOMES; DISEASE PATIENTS; CYP2C19; CLOPIDOGREL; CYP2D6; METABOLISM;
D O I
10.1186/1471-2350-15-83
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: Cytochrome P450 (CYP) 2C19 is a very important drug metabolizing enzyme. Although the single nucleotide polymorphisms (SNPs) of CYP2C19 G681A and G636A have been suggested that they may increase the incidence of cardiovascular events, the relationship between SNPs in CYP2C19 and cerebral ischemic stroke (CIS) are unclear. The aim of this study was to investigate the correlation between the distribution of G681A and G636A polymorphisms in CYP2C19 gene and the risk of CIS in Chinese. Methods: The peripheral blood DNA was extracted from 299 patients with CIS and 295 healthy controls. The genotyping was conducted using the polymerase chain reaction-restriction fragment length polymorphism. The sampled sequencing was applied to verify the correctness of genotyping results. Both the genotype and allele distributions were compared in patients with CIS and healthy controls. Results: The frequencies of CYP2C19 681AA (11.7% vs. 2.7%; P = 0.000), 636AA (4.0% vs. 0.7%; P = 0.007), 636AG (7.0% vs. 2.2%; P = 0.038) genotype, CYP2C19 681A (30.9% vs. 20.8%; P = 0.000) and 636A (13.0% vs. 5.8%; P = 0.000) allele in the CIS group are significantly higher than those in the controls. The frequencies of CYP2C19 681AA (16.7% vs. 8.6%; P = 0.036), CYP2C19 636AA (7.0% vs. 2.2%; P = 0.038) genotype, CYP2C19 681A (36.4% vs. 27.6%; P = 0.023) and CYP2C19 636A (17.5% vs. 10.3%; P = 0.010) allele in the recurrent stroke group are significantly higher than those in the first onset group. Multivariate logistic regression analysis of risk factors for cerebral ischemic stroke and recurrent stroke respectively suggests that the CYP2C19 681AA genotype may be an independent risk factor for CIS (OR = 6.179, 95% CI: 2.285 similar to 16.708; P = 0.000) and recurrent stroke (OR = 2.305, 95% CI: 1.121 similar to 4.743; P = 023). Conclusions: The AA genotype and A allele of CYP2C19 G681A may be related to the occurrence and recurrence of cerebral ischemic stroke.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Cytochrome P450 2C19 genetic polymorphisms in Ugandans
    Miura, Jun
    Obua, Celestino
    Abbo, Catherine
    Kaneko, Sunao
    Tateishi, Tomonori
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (03) : 319 - 320
  • [2] Cytochrome P450 2C19 genetic polymorphisms in Ugandans
    Jun Miura
    Celestino Obua
    Catherine Abbo
    Sunao Kaneko
    Tomonori Tateishi
    [J]. European Journal of Clinical Pharmacology, 2009, 65 : 319 - 320
  • [3] Association between cytochrome p450 (CYP) 2C19 polymorphisms and harm avoidance in Japanese
    Yasui-Furukori, Norio
    Kaneda, Ayako
    Iwashima, Kumiko
    Saito, Manabu
    Nakagami, Taku
    Tsuchimine, Shoko
    Kaneko, Sunao
    [J]. AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2007, 144B (06) : 724 - 727
  • [4] Association between cytochrome P450 promoter polymorphisms and ischemic stroke
    Kim, Su Kang
    Yim, Sung-Vin
    Lee, Byung-Cheol
    [J]. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2012, 3 (02) : 261 - 268
  • [5] Association of Cytochrome P450 2C19 polymorphisms with ischemic and bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention
    Gjermeni, Diona
    Szabo, Sofia
    Anfang, Viktoria
    Vetter, Hannah Theresa
    Juelch, Carina
    Leggewie, Stefan
    Hesselbarth, David
    Trenk, Dietmar
    Duerschmied, Daniel
    Olivier, Christoph B.
    [J]. CARDIOVASCULAR RESEARCH, 2022, 118 (SUPP 2)
  • [6] Genetic Polymorphisms of Cytochrome P450 2C19 in Functional Dyspeptic Patients Treated with Cimetidine
    Kim, Minhee
    Kong, Eunhee
    [J]. KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, 2012, 16 (05): : 339 - 342
  • [7] Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19
    R Timm
    R Kaiser
    J Lötsch
    U Heider
    O Sezer
    K Weisz
    M Montemurro
    I Roots
    I Cascorbi
    [J]. The Pharmacogenomics Journal, 2005, 5 : 365 - 373
  • [8] Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status
    Ikeda, Y
    Umemura, K
    Kondo, K
    Sekiguchi, K
    Nakashima, M
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (06) : 587 - 588
  • [9] Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
    Zeruesenay Desta
    Xiaojiong Zhao
    Jae-Gook Shin
    David A. Flockhart
    [J]. Clinical Pharmacokinetics, 2002, 41 : 913 - 958
  • [10] Association between cytochrome P450 2C19 681G>A polymorphisms and risk of cardiovascular events in coronary heart disease with clopidogrel in Chinese
    Yuan, J.
    Tang, X. F.
    Yang, Y. J.
    Gao, R. L.
    [J]. EUROPEAN HEART JOURNAL, 2011, 32 : 238 - 238